Literature DB >> 18299921

Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction.

Jan Johansson1, Pauline Djerf, Stefan Oberg, Thomas Zilling, Christer Staël von Holstein, Folke Johnsson, Bruno Walther.   

Abstract

BACKGROUND: Adenocarcinoma at the gastroesophageal junction may be regarded as of esophageal or of gastric origin, and tumor removal may follow the principles of esophagectomy or extended gastrectomy. We determined the impact of this strategy on our patients with tumors at this site.
METHODS: Baseline patient and tumor characteristics were collected, and tumors were categorized according to Siewert's classification (I, II, or III) of gastroesophageal junction tumors. Totally, 133 patients were operated on between 1990 and 2001. Ninety-six patients with type I (n = 67), II (n = 26), and III (n = 3) tumors underwent esophagectomy and gastric tube reconstruction, and 37 patients with type I (n = 5), II (n = 26), and III (n = 6) tumors underwent extended gastrectomy and long Roux-en-Y reconstructions.
RESULTS: After adjusting for the independently significant impact factors-tumor stage, tumor dissection (R0-R2), and length of tumor free resection margins-we did not find any specific survival benefit associated with either of the two evaluated surgical approaches for tumor resection and reconstruction. The EORTC quality of life forms revealed good results as indicated by the functional scales and the symptom scales.
CONCLUSIONS: Provided that adequate tumor dissection is performed, patients with adenocarcinoma at the gastroesophageal junction can be resected and reconstructed using the principles for esophagectomy or extended gastrectomy.

Entities:  

Mesh:

Year:  2008        PMID: 18299921     DOI: 10.1007/s00268-008-9470-7

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  12 in total

Review 1.  Two-field dissection is enough for esophageal cancer.

Authors:  S Law; J Wong
Journal:  Dis Esophagus       Date:  2001       Impact factor: 3.429

2.  Classification of adenocarcinoma of the oesophagogastric junction.

Authors:  J R Siewert; H J Stein
Journal:  Br J Surg       Date:  1998-11       Impact factor: 6.939

Review 3.  Cancer of the esophagogastric junction.

Authors:  H J Stein; M Feith; J R Siewert
Journal:  Surg Oncol       Date:  2000-07       Impact factor: 3.279

4.  Health-related quality of life measured by the EORTC QLQ-C30--reference values from a large sample of Swedish population.

Authors:  H Michelson; C Bolund; B Nilsson; Y Brandberg
Journal:  Acta Oncol       Date:  2000       Impact factor: 4.089

Review 5.  Individualised surgical treatment of patients with an adenocarcinoma of the distal oesophagus or gastro-oesophageal junction.

Authors:  J B F Hulscher; J J B van Lanschot
Journal:  Dig Surg       Date:  2005-05-16       Impact factor: 2.588

6.  Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome.

Authors:  Andrew P Barbour; Nabil P Rizk; Mithat Gonen; Laura Tang; Manjit S Bains; Valerie W Rusch; Daniel G Coit; Murray F Brennan
Journal:  Ann Surg Oncol       Date:  2006-11-08       Impact factor: 5.344

7.  Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma.

Authors:  T Lerut; P Nafteux; J Moons; W Coosemans; G Decker; P De Leyn; D Van Raemdonck; N Ectors
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

8.  Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus.

Authors:  Jan B F Hulscher; Johanna W van Sandick; Angela G E M de Boer; Bas P L Wijnhoven; Jan G P Tijssen; Paul Fockens; Peep F M Stalmeier; Fiebo J W ten Kate; Herman van Dekken; Huug Obertop; Hugo W Tilanus; J Jan B van Lanschot
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

9.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

10.  Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome.

Authors:  Andrew P Barbour; Nabil P Rizk; Mithat Gonen; Laura Tang; Manjit S Bains; Valerie W Rusch; Daniel G Coit; Murray F Brennan
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

View more
  10 in total

1.  Gastric tube reconstruction reduces postoperative gastroesophageal reflux in adenocarcinoma of esophagogastric junction.

Authors:  Xiu-Feng Chen; Bo Zhang; Zhi-Xin Chen; Jian-Kun Hu; Bin Dai; Fang Wang; Hong-Xin Yang; Jia-Ping Chen
Journal:  Dig Dis Sci       Date:  2011-09-28       Impact factor: 3.199

2.  Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma.

Authors:  Hiroharu Yamashita; Yasuyuki Seto; Takeshi Sano; Hiroyasu Makuuchi; Nobutoshi Ando; Mitsuru Sasako
Journal:  Gastric Cancer       Date:  2016-10-28       Impact factor: 7.370

Review 3.  Systematic review of the predictors of positive margins in gastric cancer surgery and the effect on survival.

Authors:  Hamid Reza Raziee; Roberta Cardoso; Rajini Seevaratnam; Alyson Mahar; Lucy Helyer; Calvin Law; Natalie Coburn
Journal:  Gastric Cancer       Date:  2011-12-03       Impact factor: 7.370

4.  The clinicopathologic characteristics and prognostic factors of gastroesophageal junction tumors according to Siewert classification.

Authors:  Bala Başak Öven Ustaalioğlu; Metin Tilki; Ali Sürmelioğlu; Ahmet Bilici; Can Gönen; Recep Ustaalioğlu; Özlem Balvan; Mehmet Aliustaoğlu
Journal:  Turk J Surg       Date:  2017-03-01

5.  Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?

Authors:  Susanne Blank; Thomas Schmidt; Patrick Heger; Moritz J Strowitzki; Leila Sisic; Ulrike Heger; Henrik Nienhueser; Georg Martin Haag; Thomas Bruckner; André L Mihaljevic; Katja Ott; Markus W Büchler; Alexis Ulrich
Journal:  Gastric Cancer       Date:  2017-07-06       Impact factor: 7.370

6.  Long-term survival from adenocarcinoma of the esophagus after transthoracic and transhiatal esophagectomy.

Authors:  Kjell K Ovrebo; Stein A Lie; Ole D Laerum; Knut Svanes; Asgaut Viste
Journal:  World J Surg Oncol       Date:  2012-06-30       Impact factor: 2.754

7.  Gastrectomy compared to oesophagectomy for Siewert II and III gastro-oesophageal junctional cancer in relation to resection margins, lymphadenectomy and survival.

Authors:  Joonas H Kauppila; Karl Wahlin; Jesper Lagergren
Journal:  Sci Rep       Date:  2017-12-19       Impact factor: 4.379

8.  Health-related quality of life after gastrectomy, esophagectomy, and combined esophagogastrectomy for gastroesophageal junction adenocarcinoma.

Authors:  Joonas H Kauppila; Cecilia Ringborg; Asif Johar; Jesper Lagergren; Pernilla Lagergren
Journal:  Gastric Cancer       Date:  2017-08-29       Impact factor: 7.370

9.  Proximal Gastrectomy versus Total Gastrectomy for Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Comprehensive Analysis of Data from the SEER Registry.

Authors:  Kaixuan Zhu; Yingying Xu; Jiaxin Fu; Farah Abdidahir Mohamud; Zongkui Duan; Siyuan Tan; Zekun Zhao; Ping Chen; Liang Zong
Journal:  Dis Markers       Date:  2019-12-31       Impact factor: 3.434

10.  Impact of Surgical Margin Status on Survival in Gastric Cancer: A Systematic Review and Meta-Analysis.

Authors:  Zhiyuan Jiang; Chunyu Liu; Zhaolun Cai; Chaoyong Shen; Yuan Yin; Xiaonan Yin; Zhou Zhao; Mingchun Mu; Yiqiong Yin; Bo Zhang
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.